Orexa is a clinical-stage pharmaceutical company developing a proprietary oral formulation based on a well-known anesthetic to increase food intake in patients. The company is conducting Phase 2 studies for conditions such as Post-Operative Ileus, Anorexia Nervosa, and Cachexia, aiming to improve patient health and reduce hospital stays.
Funding
$4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients suffering from conditions like Post-Operative Ileus, Anorexia Nervosa, and Cachexia often experience reduced food intake, leading to prolonged hospital stays, increased healthcare costs, and compromised health outcomes. Current treatments may not effectively stimulate appetite or address the underlying causes of diminished food consumption in these patient populations.
Solution
Orexa is developing a proprietary oral formulation, based on a well-known anesthetic, designed to increase food intake in patients suffering from conditions that lead to reduced appetite. The company's therapeutic approach aims to improve patient health, shorten hospital stays, and reduce overall healthcare costs associated with malnutrition and inadequate food consumption. Orexa is currently conducting Phase 2 clinical studies for Post-Operative Ileus and Anorexia Nervosa, with plans to initiate a Phase 2 study for Cachexia. By directly addressing the physiological mechanisms that regulate appetite, Orexa's investigational drug seeks to provide a targeted solution for patients struggling with insufficient food intake.
Target Audience
The primary target audience includes patients suffering from Post-Operative Ileus, Anorexia Nervosa, and Cachexia, as well as healthcare providers seeking effective therapeutic options to improve nutritional intake and overall health outcomes in these patient populations.
Features
- Proprietary oral formulation based on a well-established anesthetic agent.
- Targeted drug delivery designed to stimulate appetite and increase food intake.
- Phase 2 clinical trials underway for Post-Operative Ileus, with first patient dosed in January 2024.
- Phase 2 clinical trials in preparation for Anorexia Nervosa, expected to begin in Q1 2025.
- Phase 2 clinical trials in preparation for Cachexia.